Managed Care

 

Innovation and Drug Reimportation: Cost, Value, and Tradeoffs — Economic, Legal, and Public Policy Implications

Innovation and Drug Reimportation: Cost, Value, and Tradeoffs — Economic, Legal, and Public Policy Implications

This supplement was generated from a unique forum that focused on the potential impact of pharmaceutical reimportation on medical innovation. The articles within will assist noneconomists in understanding why the pharmaceutical business sector relies more on the integrity of intellectual property and the ability to entice significant investments than do other business sectors.

Discussions on this topic have been heated and are particularly important, as drug costs continue to increase in the United States, and proposed solutions have the potential to be detrimental to the core of the pharmaceutical industry. The costs and benefits of drug reimportation are discussed and analyzed by the countryís top experts in these areas.

Highlights:

  • Legislation and Pharmaceutical Reimportation
  • Price Regulation and Innovation
  • Price Differentials Between Canada and the United States
  • Reimportation and the European Experience: What the United States Can Expect
  • Roundtable Discussion: Implications of Research for Public Policy

Meetings

4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015